Prolia (Denosumab) Cost in Delaware: Prices, Insurance, and Savings in 2026

What Does Prolia (Denosumab) Actually Cost in Delaware?

The wholesale acquisition cost (WAC) for a single 60 mg prefilled syringe of Prolia is approximately $1 to 825 in 2026. Because Prolia is given once every six months, annual WAC-based spend comes to about $3,650 before any insurance or discount. Cash-pay prices at Delaware retail pharmacies cluster near that WAC figure, though individual pharmacy markup varies.

That sticker price rarely reflects what patients pay out of pocket. A 2023 analysis in the Journal of Managed Care & Specialty Pharmacy found that median commercial-plan cost-sharing for physician-administered biologics fell well below list price once plan benefits and manufacturer copay cards were applied 1. Prolia is classified as a medical benefit (billed under Medicare Part B's J-code J0897) in most plans, meaning it is typically administered and billed through a physician's office or infusion center rather than dispensed at a retail pharmacy.

For uninsured patients in Delaware, Amgen's Safety Net Foundation provides Prolia at no cost to individuals who meet income thresholds (generally at or below 300% of the federal poverty level). The application requires documentation of income and a prescriber signature.

Short version: almost no one in Delaware should pay $1,825 out of pocket.

Delaware Medicaid Coverage for Prolia

Delaware Medicaid covers Prolia with prior authorization (PA). The PA process requires the prescriber to document a confirmed diagnosis of osteoporosis (typically a DXA T-score of -2.5 or lower at the hip or spine), failure or intolerance of at least one oral bisphosphonate, and absence of hypocalcemia 2.

Processing times for Delaware Medicaid PAs generally run 24 to 72 hours for standard requests and within 24 hours for urgent requests. If the initial PA is denied, Delaware Medicaid allows a formal appeal; prescribers can strengthen the appeal by including the patient's fracture history, bone mineral density trends, and a letter of medical necessity citing guideline recommendations from the American Association of Clinical Endocrinology (AACE).

Medicaid managed care organizations (MCOs) operating in Delaware, such as Highmark Health Options and AmeriHealth Caritas Delaware, follow the state's preferred drug list but may apply their own step-therapy protocols. Checking the specific MCO formulary before initiating PA paperwork saves time.

One important detail: Prolia is a physician-administered injectable, so Medicaid reimburses it under the medical benefit, not the pharmacy benefit. The billing office at the administering clinic handles claims submission directly.

Commercial Insurance and Medicare Coverage

Most major commercial insurers in Delaware, including plans from Highmark Blue Cross Blue Shield, Aetna, Cigna, and UnitedHealthcare, cover Prolia as a specialty medical benefit. Coverage usually requires the same clinical criteria as Medicaid: documented osteoporosis and prior bisphosphonate trial.

Medicare Part B covers Prolia at 80% of the allowable amount after the annual Part B deductible is met. The patient's 20% coinsurance on a single injection comes to roughly $300 to $365. Patients with Medigap (Medicare Supplement) policies that cover Part B coinsurance may owe nothing beyond their plan premium. Medicare Advantage plans set their own cost-sharing, so amounts vary by plan.

The FREEDOM trial (N=7,868), published in the New England Journal of Medicine, demonstrated that denosumab 60 mg every six months reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over 36 months compared with placebo 2. That efficacy data underpins the medical-necessity arguments insurers accept.

"Denosumab should be considered when oral bisphosphonates are contraindicated, not tolerated, or have failed to prevent fractures," the Endocrine Society's 2020 clinical practice guideline states, a position most Delaware payers reference in their coverage criteria 3.

How the Amgen Assist 360 Savings Card Works in Delaware

Amgen's Assist 360 program offers a copay savings card for commercially insured patients. Eligible patients can pay as little as $0 per Prolia injection, with the card covering up to $1 to 700 in copay or coinsurance costs per injection. The card is valid for up to 24 months of treatment (four injections).

Eligibility requirements are straightforward. The patient must have commercial insurance (not Medicare, Medicaid, or any other government-funded plan), be a resident of the United States, and have a valid Prolia prescription. Enrollment is done online or by phone, and the card is linked to the patient's account at the administering provider's office.

Delaware patients should note that the savings card applies at the point of billing. The physician's office or clinic registers the card, and the copay reduction appears on the explanation of benefits. Patients do not need to present a physical card at each visit after initial enrollment.

Patients who exhaust the savings card benefit or lose commercial coverage mid-treatment can transition to the Amgen Safety Net Foundation. Gaps in denosumab therapy carry real clinical risk: the FREEDOM extension study showed that discontinuation of denosumab led to a rebound increase in bone turnover markers and a rise in vertebral fracture incidence within 12 months of the last dose 4. Maintaining continuous access is not optional.

Compounded Denosumab in Delaware: Legality and Availability

Compounded denosumab is available in Delaware through licensed 503A compounding pharmacies. Under federal law (the Drug Quality and Security Act of 2013), 503A pharmacies may compound medications based on individual patient prescriptions when a prescriber determines that a compounded preparation is medically appropriate 5.

Delaware does not impose state-level restrictions beyond federal 503A requirements, meaning a licensed compounding pharmacy operating in Delaware (or shipping into Delaware under applicable interstate compounding rules) can prepare denosumab formulations. Cost savings can be significant: compounded denosumab has been quoted at $300 to $600 per dose in some markets, a fraction of the brand WAC.

There are considerations patients should weigh. Compounded biologics are not FDA-approved products. They do not undergo the same lot-by-lot release testing, stability studies, or post-market surveillance as branded Prolia. The FDA has stated that compounding of complex proteins raises unique quality concerns compared with small-molecule drugs.

Patients considering compounded denosumab should verify that the pharmacy holds a current Delaware Board of Pharmacy license, operates under 503A (patient-specific prescriptions) or 503B (outsourcing facility) registration, and follows USP standards for sterile compounding. Asking for a certificate of analysis for each batch is reasonable.

Telehealth Prescribing of Prolia in Delaware

Delaware permits telehealth prescribing of Prolia. A clinician licensed in Delaware can evaluate a patient via synchronous video visit, review bone density results and lab work, and write a prescription for denosumab. The injection itself must still be administered in person (subcutaneous injection by a healthcare professional), but the prescribing visit, follow-up monitoring, and PA coordination can all happen remotely.

This matters for patients in Sussex County and other parts of southern Delaware where endocrinology and rheumatology specialists are less concentrated. Telehealth eliminates travel to Wilmington or Newark for the consultation portion of care.

Delaware's telehealth parity law (Title 18, Section 3370) requires commercial insurers to cover telehealth visits at the same reimbursement rates as in-person visits, so patients should not face higher copays for a virtual osteoporosis consultation.

Step-by-Step: Reducing Your Prolia Cost in Delaware

The approach to minimizing out-of-pocket cost depends on your insurance status.

Commercially insured patients: Enroll in the Amgen Assist 360 copay card first. Confirm that your plan covers Prolia under the medical benefit. Ask your prescriber's office to submit PA if required. The combination of insurance coverage and the savings card often results in $0 patient responsibility.

Medicare beneficiaries: Prolia is covered under Part B. If your 20% coinsurance is a barrier, check whether your Medigap policy covers Part B coinsurance. Medicare Part D Extra Help (Low-Income Subsidy) does not apply here because Prolia is a Part B drug, but state pharmaceutical assistance programs may help. Delaware has no state-specific pharmaceutical assistance program for Medicare beneficiaries as of 2026, so the Amgen Safety Net Foundation is the primary fallback for income-qualifying patients.

Medicaid enrollees: Your cost-sharing is minimal or zero once PA is approved. Contact your MCO's pharmacy services line to confirm formulary placement and PA requirements before your first injection appointment.

Uninsured patients: Apply to the Amgen Safety Net Foundation. If ineligible, ask your prescriber about compounded denosumab through a licensed 503A pharmacy, and request pricing from at least two pharmacies to compare.

Comparing Denosumab Cost to Alternatives in Delaware

Oral bisphosphonates are the most common first-line treatments for osteoporosis and are dramatically cheaper. Generic alendronate (70 mg weekly) costs $4 to $15 per month at most Delaware pharmacies. Generic risedronate runs $15 to $40 per month.

Zoledronic acid (Reclast), an IV bisphosphonate given once yearly, has a WAC of approximately $1,200 per infusion but is also available as a generic for $200 to $500 per infusion at Delaware infusion centers. Annual cost is comparable to or lower than Prolia.

A cost-effectiveness analysis published in Osteoporosis International found that denosumab became cost-effective compared with oral bisphosphonates primarily in patients at very high fracture risk (prior vertebral fracture, T-score below -3.0, or age over 75 with additional risk factors) 6. For patients who tolerate oral bisphosphonates and have moderate fracture risk, the price difference is hard to justify on efficacy grounds alone: the FREEDOM trial showed NNT of 21 for vertebral fracture prevention over three years 2.

"For patients at very high fracture risk, initial treatment with a bone-forming agent such as romosozumab or teriparatide, followed by an antiresorptive, may be more appropriate than starting with denosumab or a bisphosphonate," according to the AACE 2020 guidelines 7. Delaware patients should discuss fracture risk stratification with their prescriber before defaulting to the most expensive option.

What Happens If You Stop Prolia: Cost Implications of Discontinuation

Stopping Prolia is not like stopping a statin. Bone turnover markers rebound rapidly, and vertebral fracture risk increases within 7 to 12 months of the last injection. The FREEDOM extension data showed that patients who discontinued denosumab after long-term use experienced multiple vertebral fractures at a rate exceeding their pre-treatment baseline 4.

Current guidelines recommend transitioning to a bisphosphonate (typically zoledronic acid 5 mg IV, one or two doses) after discontinuing denosumab to prevent rebound bone loss 3. This adds a one-time cost of $200 to $1,200 depending on generic vs. brand and site of infusion.

The clinical takeaway with direct cost relevance: before starting Prolia, patients and prescribers should plan for either long-term continuation or a defined transition strategy. Abrupt discontinuation due to a lapse in insurance coverage or inability to afford the next injection creates genuine fracture risk. This is why maintaining access through savings cards, patient assistance programs, or compounded alternatives is more than a financial convenience.

Delaware patients changing insurance plans (for example, during open enrollment or after a job change) should coordinate the transition to ensure no gap in their six-month dosing schedule. A single missed dose can trigger the rebound effect.